Pittsburgh Researchers Have Developed A Promising Double-Barreled Treatment Strategy To Tackle Neuroblastoma

Researchers at the University of Pittsburgh and UPMC Hillman Cancer Center have developed a promising double-barreled treatment strategy to tackle neuroblastoma, an aggressive pediatric cancer affecting nerve tissue. In preclinical laboratory models, combining radiopharmaceutical therapy with CAR T-cell therapy reduced relapsed tumors by 80% more than using either approach on its own, achieving tumor control rates as high as 80%. This dual approach is particularly significant because CAR T-cell therapy—which reprograms a patient’s own immune cells to attack cancer—has historically shown limited success against solid tumors.

The two treatments work like a coordinated dynamic duo. Radiopharmaceuticals act like targeted “bounty hunters” that track down cancer cells throughout the body and deliver targeted radiation. This either weakens the tumor directly or breaks open its dense defenses, allowing the reprogrammed CAR T-cells to invade and destroy the remaining cancer. While human clinical trials are still at least two years away, scientists hope this strategy will lead to safer, more effective treatments that can eliminate stubborn, metastasized tumors without subjecting young children to intense standard chemotherapies.

Read the full article